Horizon Pharma plc, a specialty biopharmaceutical company with a portfolio of products in arthritis, inflammation and orphan diseases, announced today the presentation of data from a Phase 2 clinical study of ACTIMMUNE® (interferon gamma-1b) treatment in children with Friedreich’s ataxia (FA). Read more.
Synlogic, one of the newer biotech startups to come out of Cambridge, MA, already strung together nearly $30 million when it announced its launch in July. Now it’s topping off that round with some financial support from the Bill & Melinda Gates Foundation to help tackle some of the world’s bigger health problems. Read more.
That’s the dilemma facing drug hunters as leadership roles in biotech become more and more attractive. You may have noticed that more and more seasoned pharma executives are making the move from big pharma or big biotech to lead small biotech companies. Read more.
Cambridge-based venture capital firm Atlas Venture will split, with its life sciences and technology franchises becoming separate companies. Read more.
Zafgen today announced that it has initiated the first Phase 3 clinical trial, in the United States, with its lead product candidate, beloranib, in the treatment of Prader-Willi syndrome (PWS). PWS is a rare disease and the most common known genetic cause of life-threatening obesity. Read more.